| Business Summary | | BioSphere
Medical,
Inc.
is
pioneering
the
use
of
its
proprietary
bioengineered
acrylic
beads,
known
as
microspheres,
for
medical
applications
using
embolotherapy
techniques
and
also
to
develop
potential
applications
in
several
non-embolotherapy
applications.
The
Company's
initial
product,
Embosphere
Microspheres,
is
intended
for
use
in
passive
embolotherapy
to
block
the
blood
supply
to
hypervascularized
tumors
and
arteriovenous
malformations.
The
Company
is
also
developing
HepaSphere
SAP
Microspheres,
which
are
expandable
microspheres
for
injection
via
catheter
into
the
blood
vessels
feeding
the
liver
cancer
tumor,
through
its
wholly
owned
subsidiary,
BioSphere
Medical
Japan,
Inc. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | BSMD
is
engaged
in
the
medical
device
business,
focusing
on
the
non-surgical
treatment
of
uterine
fibroids.
Products
are
used
in
embolizing
hypervascularized
tumors,
arteriovenous
malformations
and
hemostasis.
For
the
six
months
ended
6/30/01,
revenues
totaled
$4.3
million,
up
from
$1.6
million.
Net
loss
rose
32%
to
$4.8
million.
Results
reflect
the
market
penetration
of
the
Embosphere
Microsphere
sales
in
the
U.S.,
offset
by
higher
product
commercialization
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Jean-Marie Vogel, 50 Chairman | $243K | $748K | John Carnuccio, 47 Pres,
CEO, Director | 287K | 267K | Alain Brunier, 56 Pres,
European Operations | -- | -- | Robert Palladino, 46 VP,
CFO | 194K | -- | Donald Anderson, 50 VP,
U.S. Marketing | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|